BIG
DNLI icon

Brooklyn Investment Group’s Denali Therapeutics DNLI Stock Holding History

Brooklyn Investment Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-31
Closed -$434 – 1219
2025
Q2 		$434 Buy
+31
New +$436 ﹤0.01% 3114
2025
Q1 		– Sell
-172
Closed -$3.51K – 2798
2024
Q4 		$3.51K Buy
+172
New +$4.4K ﹤0.01% 1319

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Brooklyn Investment Group's DNLI Position: Q3 2025 in Review

Brooklyn Investment Group sold out of Denali Therapeutics (DNLI) in Q3 2025, closing a stake of 31 shares — an estimated $434 sold.

Brooklyn Investment Group first reported a position in DNLI in Q4 2024 and held it in 2 quarters. The position peaked at $3.51K in Q4 2024. 240 funds tracked by Wall St. Rank hold DNLI as of Q3 2025.

  • Brooklyn Investment Group reported no remaining Denali Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 31 Denali Therapeutics shares in Q3 2025, an estimated $434.
  • Brooklyn Investment Group first reported a position in Denali Therapeutics in Q4 2024 and held it in 2 quarters.
  • Brooklyn Investment Group's Denali Therapeutics position peaked at $3.51K in Q4 2024.
  • 240 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2025.

Based on Brooklyn Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.